Apolipoprotein A-I mimetic peptides - ATVB in focus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 7, 2005, Pages 1325-1331

  Navab, Mohamad ^a   Anantharamaiah, G M ^b   Reddy, Srinivasa T ^a   Hama, Susan ^a   Hough, Greg ^a   Grijalva, Victor R ^a   Yu, Nicholas ^a   Ansell, Benjamin J ^a   Datta, Geeta ^b   Garber, David W ^b   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

apoA I; Atherosclerosis; D 4F; HDL; Inflammation; Peptide mimetics

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; D 4F; HIGH DENSITY LIPOPROTEIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; PHENYLALANINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE FUNCTION; MONKEY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; APOLIPOPROTEIN A-I; HUMANS; MOLECULAR MIMICRY; PEPTIDES; PROTEIN STRUCTURE, SECONDARY;

EID: 21544455803     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000165694.39518.95     Document Type: Short Survey

References (23)

1. Brewer HB, Remaley AT, Neufeld EB, Basso F, Joy C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1755-1760.
2. Zhang YZ, Zanotti I, Reilly MP, Click JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108: 661-663.
3. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004;101:9774-9779.
4. Nakamura K, Kennedy MA, Baldan A, Bojanic DD, Lyons K, Edwards PA. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J Biol Chem. 2004;279:45980-45989.
5. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opinion Lipidol. 2004;15:645-649.
6. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, Segrest JP. Studies of synthetic peptide analogs of amphipathic helix I: Structure of peptide/DMPC complexes. J Biol Chem. 1985;260:10248-10255.
7. Anantharamaiah GM. Synthetic peptide analogs of apolipoproteins. Methods Enzymol. 1986;128:627-647.
8. Yancey PG, Bielicki JK, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry. 1995;34:7955-7965.
9. Venkatachalapathi YV, Phillips MC, Epand RM, Epand RF, Tytler EM, Segrest JP, Anantharamaiah GM. Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins Structure Function Genet. 1993;15:349-359.
10. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res. 2001;42:1096-1104.
11. Palgunachari MN, Mishra VK, Lund-Katz S, Phillips MC, Adeyeye SO, Alluri S, Anantharamaiah GM, Segrest JP. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Arterioscler Thromb Vasc Biol. 1996;16:328-338.
12. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy S, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41: 1481-1494.
13. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495-1508.
14. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan M-L, Lusis AJ, Fogelman AM. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.
15. Datta G, Epand RF, Epand RM, Chaddha M, Kirksey MA, Garber DW, Lund-Katz S, Phillips MC, Hama S, Navab M, Fogelman AM, Palgunachari MN, Segrest JP, Anantharamaiah GM. Aromatic Residue Position on the Nonpolar Face of Class A Amphipathic Helical Peptides Determines Biological Activity. J Biol Chem. 2004;279:26509-26517.
16. Epand RM, Epand RF, Sayer BG, Melacini G, Palgunachari MN, Segrest JP, Anantharamaiah GM. An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol. Biochemistry. 2004; 43:5073-5083.
17. Epand RM, Epand RF, Sayer BG, Datta G, Chaddha M, Anantharamaiah GM. Two homologous apolipoprotein AI mimetic peptides. Relationship between membrane interactions and biological activity. J Biol Chem. 2004;279:51404-51414.
18. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, Fogelman AM, Segrest JP, Anantharamaiah GM. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 2001;42:545-552.
19. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290-292.
20. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM. Oral D-4F causes formation of pre-β High-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:r120-r125.
21. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993-1007.
22. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoproteins distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751-2756.
23. Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK. Altered activities of antiatherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res. 2002;43: 477-485.